The Technical Analyst
Ocuphire Pharma, Inc. [OCUP]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Ocuphire Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.33% $1.535
/ 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 38.09 mill |
| EPS: | -0.460 |
| P/E: | -3.34 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 24.81 mill |
| Avg Daily Volume: | 0.227 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.34 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -3.34 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.392 - 1.688 ( +/- 9.61%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Pepose Jay | Buy | 32 000 | Common Stock |
| 2024-04-11 | Pepose Jay | Buy | 48 000 | Stock Option (right to buy) |
| 2024-03-21 | Schachle Joseph K | Buy | 2 000 | Common Stock |
| 2024-03-21 | Jhaveri Nirav S. | Buy | 10 000 | Common Stock |
| 2024-03-18 | Magrath George | Buy | 25 000 | Common Stock |
| INSIDER POWER |
|---|
| 95.21 |
| Last 93 transactions |
| Buy: 3 970 384 | Sell: 115 125 |
Forecast:
16:00 - $1.530
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.530
Forecast 2: 16:00 - $1.530
Forecast 3: 16:00 - $1.530
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.535 (0.33% ) |
| Volume | 0.109 mill |
| Avg. Vol. | 0.227 mill |
| % of Avg. Vol | 48.24 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OCUP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Last 10 Buy Signals
Latest Press Releases
2024-04-22 08:00:00 - Press Release
Ocuphire Pharma Announces Apx3330 Presentation At Arvo 2024 Annual Meeting
Farmington hills, mich., april 22, 2024 (globe newswire) -- ocuphire pharma, inc. (nasdaq: ocup) (“ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that daniel su, m.d. will deliver a paper presentation on oral apx3330 at the association for research in vision and ophthalmology (arvo) annual meeting to be held may 5-9, 2024 in seattle, washington.
2024-04-11 10:03:00 - Press Release
First Patient Enrolled In Lynx-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (ps) For The Treatment Of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Lynx-2 follows spa agreement with fda development of ps is funded by ocuphire's partner viatris farmington hills, mich., april 11, 2024 (globe newswire) -- ocuphire pharma, inc. (nasdaq: ocup), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the enrollment of the first subject in the lynx-2 phase 3 registration study evaluating phentolamine ophthalmic solution 0.75% (ps) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery.
2024-04-01 07:14:00 - Press Release
Ocuphire Announces The U.s. Commercial Launch Of Ryzumvl™ (phentolamine Ophthalmic Solution 0.75%) By Its Partner Viatris
Farmington hills, mich., april 01, 2024 (globe newswire) -- ocuphire pharma, inc. (nasdaq: ocup), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the u.s. commercial launch of ryzumvi™ (phentolamine ophthalmic solution) by its partner viatris inc. (nasdaq: vtrs).
2024-03-08 08:00:00 - Press Release
Ocuphire Pharma Announces Financial Results For Fourth Quarter And Full Year 2023 And Provides Corporate Update
Farmington hills, mich., march 08, 2024 (globe newswire) -- ocuphire pharma, inc. (nasdaq: ocup), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
2024-02-23 08:00:00 - Press Release
Ocuphire Pharma To Present In The Bio Ceo & Investor Conference
Farmington hills, mich., feb. 23, 2024 (globe newswire) -- ocuphire pharma, inc. (nasdaq: ocup) (“ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that george magrath, m.d. m.b.a, m.s. ceo of ocuphire, will be presenting a company overview at the bio ceo & investor conference being held february 26-27 2024 in new york city. company management will also be participating in one-on-one meetings throughout the conference.
Latest News
2024-02-26 15:20:23 - InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
2024-02-23 08:00:00 - GlobeNewsWire
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.
2024-02-07 12:47:28 - InvestorPlace
3 Value Stocks to Buy on the Dip: February 2024
With the U.S. economy running at full steam and the labor market continuing to impress onlookers, the concept of value stocks might not be the most popular idea. After all, many of the usual suspects of 2023 are still printing strong returns.
2024-01-11 09:01:43 - Zacks Investment Research
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.
2023-11-30 07:30:00 - InvestorPlace
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
After a rocky couple of years, there finally seems to be some light at the end of the tunnel for growth stocks. Interest rates have stabilized, and the economy is again showing signs of strength.
2023-10-26 08:00:00 - GlobeNewsWire
Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
FARMINGTON HILLS, Mich., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring APX3330 and phentolamine ophthalmic solution at the American Academy of Ophthalmology Annual Meeting (AAO 2023) to take place in San Francisco, California on November 3-6, 2023. In addition, Jay Pepose, M.D. Ph.D., Chief Medical Advisor at Ocuphire, will provide a corporate overview at the Eyecelerator AAO 2023 Retina Showcase in San Francisco, California on November 2, 2023.
2023-10-06 08:00:00 - GlobeNewsWire
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy
2023-09-27 08:21:00 - Market Watch
Viatris and Ocuphire Pharma get FDA green light for eye treatment
Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye dilations are conducted in the U.S. each year to examine the retina and for other routine check-ups, the companies said in a release, but the dilation can last up to 24 hours and side effects include light sensitivity and blurred vision.
2023-08-08 08:00:00 - GlobeNewsWire
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that Ronil Patel, MS, SVP of Operations and Business Development and Charlie Hoffmann, MBA, SVP of Corporate Development, will participate in a Fireside Chat at the Canaccord 43rd Annual Growth Conference being held August 7-10, 2023 in Boston, MA and will present a company overview and participate in a panel at the H.C. Wainwright Ophthalmology Conference being held virtually on August 16, 2023.
2023-07-10 20:42:09 - InvestorPlace
Surprise! These 3 Penny Stocks Pack Powerful Financials.
Penny stocks have a horrible reputation for the most part and it's not necessarily undeserved. Too many times, charlatans hawk their junk securities, often in the over-the-counter market where regulations are far less stringent than in actual exchanges.